Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-03-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司第五届监事会第十七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the 5th Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It includes approvals of various reports and proposals such as the 2023 Supervisory Board Work Report, 2023 Financial Final Accounts Report, 2023 Profit Distribution Plan, 2024 Financial Budget Report, 2023 Annual Report (full text and summary), 2023 Fundraising Use Report, 2023 ESG Report, 2022 Restricted Stock Incentive Plan, and the change of accounting firm. The document states that these reports and proposals will be submitted to the 2023 Annual General Meeting for approval. The document itself is an announcement of the Supervisory Board's meeting resolutions and does not contain the full reports or detailed financial data. It also references that the full reports are disclosed separately on the Shanghai Stock Exchange website. The document length is 2911 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals, not the reports themselves.
2024-03-19 Chinese
长春百克生物科技股份公司2023年度募集资金存放与实际使用情况审核报告
Regulatory Filings
2024-03-19 Chinese
长春百克生物科技股份公司监事会关于2022年限制性股票激励计划首次授予第一个归属期归属名单的核查意见
Regulatory Filings
2024-03-19 Chinese
长春百克生物科技股份公司2023年度独立董事述职报告（刘静）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 of Changchun Baike Biotechnology Co., Ltd. It details the independent director's background, attendance at board and committee meetings, oversight activities, and evaluation of company governance and compliance during the year. It does not contain financial statements or quarterly/annual financial results but focuses on governance and director duties. This type of document is a report by an independent director on their annual duties and observations, which fits best under Board/Management Information (MANG) as it relates to board member activities and governance oversight rather than a full annual report or audit report. The document length is under 5,000 characters, but it is a substantive report, not a mere announcement. Therefore, the classification is MANG with high confidence.
2024-03-19 Chinese
长春百克生物科技股份公司2023年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023, including financial and non-financial internal control defects, their identification, and rectification status. The document is a detailed report on internal control evaluation, which is typically part of audit-related disclosures. It does not appear to be a full annual report (10-K) or an earnings release. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document length is 4128 characters, which is relatively short but contains detailed substantive content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2023
2024-03-19 Chinese
长春百克生物科技股份公司关于变更会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's accounting firm for the upcoming fiscal year 2024. It details the new auditor's credentials, reasons for the change, communication with the previous auditor, and the approval process by the board and audit committee. There are no financial statements or audit reports included, only information about the appointment and related procedures. The document length is 3738 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement about auditor change, but since it does not contain an actual audit report or financial data, it fits the category of Regulatory Filings (RNS) as a formal announcement of auditor change and related compliance information.
2024-03-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.